Genmab, Incyte Sign Colorectal Cancer Trial Collaboration for Colorectal Cancer Treatment

MT newswire2026/10/26 07:37

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

03:37 AM EDT, 10/26/2026 (MT Newswires) -- Genmab (GMAB) and Incyte (INCY) said Saturday they agreed to test petosemtamab with Incyte's treatment plus standard chemotherapy as a first-line treatment for metastatic colorectal cancer with a specific KRAS mutation. Genmab will run the phase 1/2 study and Incyte will co-fund it and supply its treatment drug, the companies said. Petosemtamab is an experimental bispecific antibody targeting the EGFR and LGR5 proteins, and Incyte's treatment blocks the KRAS mutation found in about 40% of colorectal cancers, they said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Intel disclosed that CEO Pat Gelsinger purchased 150,000 shares of Intel common stock on the open market on November 2nd, at a weighted average price of $64.7312 per share, with a transaction amount of approximately $9.71 million. The purchase was made through a family trust, and after the transaction, the trust's Intel holdings increased to 1.4647 million shares, up around 11.4% from before the transaction. Following the announcement, Intel’s share price briefly rallied, narrowing its decline to 1.2% before retreating again.

华尔街见闻•2026/11/04 19:17